Clinical Impact of GLP‐1 Receptor Agonists in Veterans Receiving Basal‐Bolus Insulin

2021 ◽  
Author(s):  
Olivia Hopton ◽  
Nancee Waterbury ◽  
Jason Egge ◽  
Brian C. Lund
Keyword(s):  
Clinical Impact ◽  
Receptor Agonists ◽  
Bolus Insulin ◽  
Basal Bolus

Near-Normoglycemia, with Meaningful Discontinuations of Prandial Insulin, by Adding Weekly Albiglutide (Albi) to Uncontrolled Basal/Bolus Insulin-Treated Type 2 Diabetes (T2DM)

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 1073-P ◽  
Author(s):  
JULIO ROSENSTOCK ◽  
ANTONIO J. NINO ◽  
JOSEPH SOFFER ◽  
JASON M. MALLORY ◽  
LOIS M. ERSKINE ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Prandial Insulin ◽  
Bolus Insulin ◽  
Basal Bolus

2329-PUB: Transitioning T2DM Patients to Basal-Bolus Insulin Leads to Sustainable A1C Improvement

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 2329-PUB
Author(s):  
ROMIYA BARRY ◽  
DON JOHNS ◽  
BUDDUG REES
Keyword(s):  
Bolus Insulin ◽  
Basal Bolus

PaQ®, a simple 3-day basal/bolus insulin delivery device, in people with type 2 diabetes

2013 ◽  
Author(s):  
J. K. Mader ◽  
L. C. Lilly ◽  
F. Aberer ◽  
J. Pachatz ◽  
S. Korsatko ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Delivery ◽  
Delivery Device ◽  
Bolus Insulin ◽  
Basal Bolus

Improvement in glycaemic parameters using SGLT-2 inhibitor and GLP-1 agonist in combination in an adolescent with diabetes mellitus and Prader-Willi syndrome: a case report

2020 ◽  
Vol 33 (7) ◽  
pp. 951-955 ◽  
Author(s):  
Toby Candler ◽  
David McGregor ◽  
Kruthika Narayan ◽  
Chris Moudiotis ◽  
Christine P. Burren
Keyword(s):  
Insulin Resistance ◽  
Blood Glucose ◽  
Treatment Options ◽  
Prader Willi Syndrome ◽  
Feeding Difficulties ◽  
Glucose Levels ◽  
Insulin Requirements ◽  
Bolus Insulin ◽  
Basal Bolus

AbstractObjectivesPrader-Willi Syndrome (PWS) is characterised by hyperphagia often leading to obesity; a known risk factor for insulin resistance and type 2 (T2) diabetes. We present a prepubertal girl with PWS who developed diabetes.Case presentationOur case was diagnosed with PWS in infancy following investigation for profound central hypotonia and feeding difficulties. She commenced growth hormone (GH) aged 8 years for short stature and treatment improved linear growth. At age 12 years, she presented with polydipsia, polyuria and vulvovaginitis. She was overweight (BMI SDS +1.43). Diabetes was diagnosed (Blood glucose = 24.2 mmol/L, HbA1c = 121 mmol/mol or 13.2%). She was not acidotic and had negative blood ketones. Autoantibodies typical of type 1 diabetes were negative. She was initially treated with basal bolus insulin regime. GH was discontinued 3 months later due to concerns regarding GH-induced insulin resistance. Off GH, insulin requirements reduced to zero, allowing Metformin monotherapy. However off GH, she reported significant lethargy with static growth and increased weight. Combinations of Metformin with differing insulin regimes did not improve glucose levels. Liraglutide (GLP-1 agonist) and Metformin did not improve glucose levels nor her weight. Liraglutide and Empaglifozin (SGLT-2 inhibitor) therapy used in combination were well tolerated and demonstrated rapid normalisation of blood glucose and improvement in her HbA1c to within target (48 mmol/mol) which was sustained after 6 months of treatment.ConclusionsNewer treatments for type 2 diabetes (e. g. GLP-1 agonists or SGLT-2 inhibitors) offer potential treatment options for those with diabetes and PWS when conventional treatments are ineffective.

Sign in / Sign up

Export Citation Format

Share Document